Central and peripheral vision loss associated with nefazodone usage

Documenta Ophthalmologica

Volumn 106, Issue 3, 2003, Pages 319-325

  Luu, Chi ^b,c   Kiely, Patricia ^b   Crewther, David P ^a,b   Kowal, Lionel ^d,e   Crewther, Sheila ^b  

^a SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^d ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

mfERG; mfVEP; Nefazodone; Serotonin reuptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; NEFAZODONE;

A WAVE; ADULT; ARTICLE; B WAVE; BLINDNESS; CASE REPORT; CENTRAL SCOTOMA; COLOR VISION DEFECT; DEPRESSION; DIPLOPIA; DISEASE ASSOCIATION; DISEASE DURATION; DIVERGENT STRABISMUS; DRUG WITHDRAWAL; ELECTRORETINOGRAM; EVOKED VISUAL RESPONSE; FEMALE; HALLUCINATION; HUMAN; IMAGING SYSTEM; NEUROTOXICITY; OPTIC NERVE INJURY; PATIENT REFERRAL; PHOTOSTIMULATION; RETINA INJURY; RETINA MACULA LUTEA; SENSORY SYSTEM ELECTROPHYSIOLOGY; STIMULUS RESPONSE; VISUAL ACUITY; VISUAL CORTEX; VISUAL DISORDER; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; VISUAL SYSTEM EXAMINATION;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COLOR PERCEPTION; ELECTRORETINOGRAPHY; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; RETINA; RETINAL DISEASES; TRIAZOLES; VISION DISORDERS; VISUAL ACUITY; VISUAL FIELDS;

EID: 0344089194     PISSN: 00124486     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022951526424     Document Type: Article

References (13)

1. Kraus RP. Visual 'trails' with nefazodone treatment. Am J Psychiatry 1996; 153: 1365-6.
2. Owens MJ et al. The serotonergic antidepressant nefazodone inhibits the serotonin transporter: In vivo and ex vivo studies. Life Sci 1995; 57: L373-80.
3. MIMS Australia on CD. 1997, Medimedia Australia Pty Ltd:
4. Lader MH. Tolerability and safety: Essentials in antidepressant pharmacotherapy. J Clin Psychiatry 1996; 2: 39-44.
5. Pavan-Langston D, Dunkel E. Handbook of Ocular Drug Therapy and Ocular Effects of Systemic Drugs. Boston, MA: Little, Brown and Company, 1991: 280.
6. Schwartz K. Nefazodone and visual side effects. Am J Psychiatry 1997; 154.
7. Horton JC, Trobe JD. Akinetopsia from nefazodone toxicity. Am J Ophthalmol 1999; 128: 530-1.
8. Ellingrod VL, Perry PJ. Nefazodone: A new antidepressant. Am J Health Syst Pharm 1995; 52: 2799-812.
9. Hughes MS, Lessell S. Trazodone-induced palinopsia. Arch Ophthalmol 1990; 108: 399-400.
10. Lauterbach EC, Abdelhamid A, Annandale JB. Posthallucinogen-like visual illusions (palinopsia) with risperidone in a patient without previous hallucinogen exposure: Possible relation to serotonin 5HT2a receptor blockade. Pharmacopsychiatry 2000; 33: 38-41.
11. Olyaei AJ et al. Interaction between tacrolimus and nefazodone in a stable renal transplant recipient. Pharmacotherapy 1998; 18: 1356-9.
12. Klistorner A, Crewther DP, Crewther SG. Temporal analysis of the topographic ERG: Chromatic versus achromatic stimulation. Vision Res 1998; 38: 1047-62.
13. Klistorner A, Crewther DP, Crewther SG. Separate magnocellular and parvocellular contributions from temporal analysis of the multifocal VEP. Vision Res 1997; 37: 2161-9.